|
|
Therapeutic Clinical Intelligence - PsoriasisPublished by: Austin Research Group Published: Jul. 1, 2007 - 80 Pages Table of Contents
AbstractThe world-wide market for Psoriasis therapeutics is estimated to be valued at $1-$3 billion annually. There are currently only 3 biologic competitors vying for share of this market. The Anti-TNF-a monoclonal antibodies—Enbrel, Humira, and Remicade—currently dominate the moderate-to-severe psoriasis therapeutic market. However, companies are aggressively developing both novel and second-generation compounds that have the potential to challenge the competitive position of these market leaders in the future. Potential threats on the horizon include biologic therapies such as Cimzia, CNTO-1275, Golimumab, and ABT-874 in both psoriasis and/or psoriatic arthritis. Additionally, the development landscape for small molecules could produce competitive therapeutic alternatives to Anti-TNFs. Novel compounds including BMS-582949 and Apremilast have a convenience and cost advantage over the biologics due to their oral formulation and potential attractiveness to managed care organizations and pharmacy benefit managers (payers). However it is yet to be seen if these agents will be able to demonstrate superior efficacy over the current market leaders.The Psoriasis Therapeutic Clinical Intelligence report provides an in-depth assessment of the R&D competitive landscape for psoriasis (PsO)—from a clinical perspective. Additionally, the analysis highlights select compounds in the pipeline for Psoriatic Arthritis (PsA). The scope of the report focuses on competitive biologic and novel small molecule products in development and specifically captures key data on clincial trial design and data results for the products that have the potential to alter the market dynamics in psoriasis over the next 3-7 years. This methodological approach is intended to provide insight into the strategic opportunities and challenges, as well as the clinical hurdles facing PsO/PsA drug developers. Clients utilize the report as a resource to support key decisions including:
Product Overview: Mechanism of Action, Developing Companies, Indications and Phase of Development. Clinical Trial Assessments: Detailed evaluations of completed and ongoing competitor studies that capture key elements of the study protocol including:
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||